Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 53, Issue 1, 2000, Pages 15-18

  Kolar Z ^a   Murray, P G ^b   Scott, K ^c   Harrison, A ^c   Vojtesek B ^d   Dusek J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c NEW CROSS HOSPITAL   (United Kingdom)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Androgen receptor; Bcl 2; Cyclin D1; Hormone independency; p21WAF1 CIP1; Prostatic cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYCLIN D1; PROTEIN BCL 2; PROTEIN P21;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RECEPTOR DENSITY;

CYCLIN D1; GENES, BCL-2; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHOTRANSFERASES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0033959495     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.53.1.15     Document Type: Article

References (26)

1. 1 Deneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer 1993;71:1089-97.
2. 2 Stearns ME, McGarvey T. Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest 1992;67:540-52.
3. 3 Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol 1997;8:21-7.
4. 4 Kyprianou N, English HF, Isaacs JT. Activation of Ca2+/Mg2+ dependent endonucleases as an early event in castration-induced prostatic cell death. Prostate 1989;13: 103-18.
5. 5 Hochenberry DM, Nunez G, Milliman C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
6. 6 Bubendorf L, Sauter G, Moch H, et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996;148:1557-65.
7. 7 Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
8. 8 Magi-Galluzzi C, Montironi R, Giannulis G, et al. Prostatic invasive adenocarcinoma: effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol Res Pract 1993;189:1154-60.
9. 9 Montironi R, Magi-Galluzzi C, Diamanti L, et al. Prostatic intra-epithelial neoplasia: expression and location of proliferating cell nuclear antigen (PCNA) in epithelial, endothelial and stromal nuclei. Virchows Arch 1993;422:185-92.
10. 10 Montironi R, Magi-Galluzzi C, Fabris G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 1995;191:873-80.
11. 11 Armas OA, Melamed A, Aprikian A, et al. Effect of preoperative androgen deprivation therapy in prostatic carcinoma. Lab Invest 1993;68:55A.
12. 12 Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143: 390-400.
13. 13 Kyprianou N, Bains AK, Jacobs SC. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 1994;25:66-75.
14. 14 Montironi R, Magi-Galluzzi C, Muzzonigro G, et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13.
15. 15 Cox LS. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. J Pathol 1997;183:134-40.
16. 16 Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992;71:505-14.
17. 17 Fredersdorf S, Milne AW, Hall PA, et al. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996;148:825-35.
18. 18 Li R, Waga S, Hannon GJ, et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-7.
19. 19 Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
20. 20 El Deiry WS, Tokino T, Velculeccu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
21. 21 Rey MJ, Fernandez PL, Jares P, et al. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol 1998;184:265-71.
22. 22 Kallakury BVS, Sheehan CE, Ambros RA, et al. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997;80: 753-63.
23. 23 Barnes DM. Cyclin D1 in mammary carcinoma. J Pathol 1997;181:267-69.
24. 24 Chodak GW, Krane DM, Puy LA, et al. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992;147:798-803.
25. 25 Habib FK, Odoma S, Busuttil A, et al. Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor. Cancer Res 1986;47:2351-6.
26. 26 Chen Y, Robles AI, Martinez LA, et al. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996;7:1571-8.